Multiple anti-atherosclerotic treatments impair aspirin compliance: Effects on aspirin resistance

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 10, 2008, Pages 1832-1834

  Pignatelli, P ^a   Di Santo, S ^a   Barilla F ^a   Gaudio, C ^a   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; THROMBOXANE A2;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG RESPONSE; HUMAN; LABORATORY TEST; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS;

ARACHIDONIC ACID; ASPIRIN; ATHEROSCLEROSIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; PATIENT COMPLIANCE; PLATELET ACTIVATION; THROMBOXANE A2;

EID: 52649141014     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03122.x     Document Type: Letter

References (14)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on aspirin resistance. Aspirin resistance: Position paper of the Working Group on aspirin resistance. J Thromb Haemost 2005; 3: 1309-11.
3. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart 2007; 153: 175-81.
4. Frelinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-indipendent pathway. A 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-96.
5. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258-63.
6. Violi F, Pignatelli P. Aspirin resistance: Is this term meaningful? Curr Opin Hematol 2006; 13: 331-6.
7. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705-9.
8. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, De Franco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973-5.
9. Cattaneo M. Laboratory detection of 'aspirin resistance': What test should we use (if any)? Eur Heart J 2007; 28: 1673-5.
10. Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, TrifiròE, Di Renzo L, Violi F. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005; 3: 2784-9.
11. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
12. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203-12.
13. Cramer JA. Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence. Am J Manag Care 1998; 4: 1563-8.
14. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-9.